Evotec Receives US$ 25 Million Milestone Payment from Bristol Myers Squibb for Progress in Neurodegenerative Disease Partnership

Evotec Receives US$ 25 Million Milestone Payment from Bristol Myers Squibb for Progress in Neurodegenerative Disease Partnership

(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research into disease-modifying therapies. Since its launch in 2016, the collaboration has produced several promising programs, including EVT8683 (BMS-986419), which completed Phase 1 trials. The partnership was extended in 2023 for eight more years. Evotec’s Chief Scientific Officer, Dr. Cord Dohrmann, highlighted the shared goal of developing therapies that go beyond symptom management to bring real clinical benefit to patients suffering from neurodegenerative disorders.

(PRESS RELEASE) HAMBURG, 27-Oct-2025 — /EuropaWire/ — Evotec SE has announced a milestone in its long-standing neuroscience partnership with Bristol Myers Squibb, receiving a US$ 25 million payment in recognition of scientific progress achieved within their joint research programs targeting neurodegenerative diseases. The funds will support continued advancement of the companies’ preclinical pipeline and further development of innovative treatments aimed at modifying the course of these challenging conditions.

The collaboration, first launched in 2016, focuses on discovering and developing disease-modifying therapies for neurodegenerative disorders, an area where effective treatment options remain scarce. Over the years, the partnership has built a robust portfolio of promising candidates, including EVT8683—licensed by Bristol Myers Squibb in 2021 and now known as BMS-986419—which has successfully completed Phase 1 clinical trials. The collaboration was renewed in 2023 for an additional eight years, underscoring both companies’ commitment to addressing unmet medical needs in neuroscience.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the significance of the latest achievement, stating: “Patients affected by neurodegenerative conditions need therapies that move beyond symptom management. This milestone deepens our collaboration with Bristol Myers Squibb as we continue to transform cutting-edge disease biology into therapeutic possibilities. Our joint mission remains to deliver meaningful and lasting solutions for patients worldwide.”

This partnership exemplifies Evotec’s continued leadership in translational drug discovery, combining scientific innovation with strategic collaboration to accelerate the development of next-generation treatments for complex neurological diseases.

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com

Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

SOURCE: Evotec